MENU
+Compare
CRVS
Stock ticker: NASDAQ
AS OF
Dec 17, 04:59 PM (EDT)
Price
$7.42
Change
+$0.52 (+7.54%)
Capitalization
474.86M

CRVS Corvus Pharmaceuticals Forecast, Technical & Fundamental Analysis

a provider of anticancer immuno-oncology drugs

Industry Biotechnology
CRVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
a Summary for CRVS with price predictions
Dec 17, 2024

CRVS sees MACD Histogram just turned negative

CRVS saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 12, 2024. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 43 instances where the indicator turned negative. In of the 43 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on December 03, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on CRVS as a result. In of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

CRVS moved below its 50-day moving average on December 13, 2024 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for CRVS crossed bearishly below the 50-day moving average on December 16, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRVS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for CRVS entered a downward trend on December 17, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CRVS's RSI Oscillator exited the oversold zone, of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CRVS advanced for three days, in of 240 cases, the price rose further within the following month. The odds of a continued upward trend are .

CRVS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CRVS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (35.714) is normal, around the industry mean (14.664). P/E Ratio (0.000) is within average values for comparable stocks, (87.689). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.783). CRVS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (0.000) is also within normal values, averaging (260.687).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

View a ticker or compare two or three
CRVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

CRVS is expected to report earnings to fall 80.67% to -11 cents per share on March 06

Corvus Pharmaceuticals CRVS Stock Earnings Reports
Q4'24
Est.
$-0.12
Q3'24
Missed
by $0.49
Q2'24
Beat
by $0.05
Q1'24
Est.
$-0.12
Q4'23
Missed
by $0.02
The last earnings report on November 12 showed earnings per share of -60 cents, missing the estimate of -10 cents. With 1.37M shares outstanding, the current market capitalization sits at 474.86M.
A.I. Advisor
published General Information

General Information

a provider of anticancer immuno-oncology drugs

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
863 Mitten Road
Phone
+1 650 900-4520
Employees
28
Web
https://www.corvuspharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SMVZX13.52N/A
N/A
Virtus Ceredex Mid-Cap Value Equity R6
ICHKX12.80-0.02
-0.16%
Guinness Atkinson China & Hong Kong
ADGZX25.93-0.14
-0.54%
AB Core Opportunities Z
HDVTX10.79-0.06
-0.55%
Hartford International Equity R5
LGLUX51.84-0.38
-0.73%
Lord Abbett Growth Leaders R5

CRVS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, CRVS has been loosely correlated with VRDN. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if CRVS jumps, then VRDN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRVS
1D Price
Change %
CRVS100%
+7.10%
VRDN - CRVS
38%
Loosely correlated
-3.34%
FULC - CRVS
34%
Loosely correlated
+2.71%
VCYT - CRVS
33%
Poorly correlated
-2.52%
CYTK - CRVS
32%
Poorly correlated
-2.53%
KROS - CRVS
32%
Poorly correlated
-7.31%
More